First-Ever European Analysis of Electronic Brachytherapy Using the Xoft System for Endometrial and Cervical Cancer Treatment to be Presented at European Society for Radiotherapy & Oncology Meeting
(Thomson Reuters ONE) -
Preliminary results show targeted treatment offers low toxicity for patients
with endometrial or cervical cancer
NASHUA, N.H. and VIENNA, Austria, May 05, 2017 (GLOBE NEWSWIRE) -- (Booth
#4330) - iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced
image analysis, workflow solutions and radiation therapy for the early
identification and treatment of cancer, today announced researchers will present
new clinical data supporting use of the Xoft® Axxent® Electronic Brachytherapy
(eBx®) System® for the treatment of endometrial and cervical cancer at the
36(th) Congress of the European Society for Radiotherapy & Oncology (ESTRO) in
Vienna, Austria, from May 5-9, 2017. The Company will also showcase the multi-
platform Xoft System and its suite of products at its booth (#4330) throughout
the meeting.
"This new clinical data analysis of endometrial and cervical cancer patients
treated with the Xoft System at a European facility presents encouraging results
that support the valuable benefits of this innovative treatment option," said
Ken Ferry, CEO of iCAD. "These new preliminary data add to the growing body of
global research highlighting the Xoft System's clinical value to patients and
clinicians alike."
At the meeting, researchers from Miguel Servet University Hospital in Zaragoza,
Spain will present new preliminary findings on their recent clinical experience
treating endometrial and cervical cancer patients with electronic brachytherapy
using the Xoft System in two posters including E-poster EP-1783 entitled "Acute
toxicity with Xoft Axxent Electronic Brachytherapy (XB) in endometrial or
cervical cancer." This study demonstrated excellent results in acute toxicity in
29 endometrial or cervical cancer patients treated with the Xoft System from
September 2015 to September 2016. In the second study, Poster PO-0939, entitled
"Comparison of brachytherapy sources of endometrial cancer: Electronic
brachytherapy source and 192Ir" researchers performed a dosimetric analysis.
Results showed that electronic brachytherapy delivered a lower dose of radiation
to surrounding healthy organs at risk, such as the bladder and rectum, than
would have been delivered had 192Ir been utilized instead of the Xoft System.
The posters will be available for viewing during the conference.
"The Xoft System is able to precisely target cancer cells and spare surrounding
healthy tissue, resulting in a significant reduction in the radiation dose that
reaches organs at risk," said Agustina Mendez Villamon, MD, Radiation
Oncologist, Miguel Servet University Hospital. "Our early results with this
targeted technology are very promising, and we are pleased to offer this
valuable treatment option to appropriately selected patients with endometrial
and cervical cancer in Spain."
The Xoft System is FDA cleared, CE marked, and licensed in a growing number of
countries for the treatment of cancer anywhere in the body, including early-
stage breast cancer, gynecological cancers and non-melanoma skin cancer.
About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment that is FDA cleared, CE
marked, and licensed in a growing number of countries for the treatment of
cancer anywhere in the body, including treatment of early-stage breast cancer,
gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary
miniaturized x-ray as the radiation source that delivers precise treatment
directly to cancerous areas while sparing healthy tissue and organs. The Xoft
System requires only minimal shielding and therefore does not require room
redesign or construction investment. Minimal shielding also allows medical
personnel to remain in the room with the patient during treatment. The mobility
of the Xoft System makes it easy to treat patients at multiple locations and to
easily store the system when not in use. The Axxent Hub is a cloud-based
oncology collaboration software solution that enables centers to monitor
treatment workflow and enhance communication between clinical specialists. Xoft
is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft
visit www.xoftinc.com, like us on Facebook or follow us on Twitter at (at)xofticad.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and
services that enable clinicians to find and treat cancers earlier and faster
while improving patient outcomes. iCAD offers a comprehensive range of
upgradeable computer aided detection (CAD) and workflow solutions to support
rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's
Xoft® Axxent® Electronic Brachytherapy (eBx®) System® delivers high dose rate,
low energy radiation, which targets cancer while minimizing exposure to
surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use
anywhere in the body, including treatment of non-melanoma skin cancer, early-
stage breast cancer and gynecological cancers. The comprehensive iCAD technology
platforms include advanced hardware and software as well as management services
designed to support cancer detection and radiation therapy treatments. For more
information, visit or www.icadmed.com or www.xoftinc.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995
Certain statements contained in this News Release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to the
Company's ability to defend itself in litigation matters, to achieve business
and strategic objectives, the risks of uncertainty of patent protection, the
impact of supply and manufacturing constraints or difficulties, uncertainty of
future sales levels, protection of patents and other proprietary rights, the
impact of supply and manufacturing constraints or difficulties, product market
acceptance, possible technological obsolescence of products, increased
competition, litigation and/or government regulation, changes in Medicare or
other reimbursement policies, risks relating to our existing and future debt
obligations, competitive factors, the effects of a decline in the economy or
markets served by the Company; and other risks detailed in the Company's filings
with the Securities and Exchange Commission. The words "believe", "demonstrate",
"intend", "expect", "would", "could", "consider", "project", "estimate", "will",
"continue", "anticipate", "likely", "seek", and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance on
those forward-looking statements, which speak only as of the date the statement
was made. The Company is under no obligation to provide any updates to any
information contained in this release. For additional disclosure regarding these
and other risks faced by iCAD, please see the disclosure contained in our public
filings with the Securities and Exchange Commission, including the 10-K for the
year ended December 31, 2016, available on the Investors section of our website
at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.
Contact:
For iCAD investor relations:
LifeSci Advisors
Bob Yedid, (646)-597-6989
Bob(at)lifesciadvisors.com
or
For iCAD media inquiries:
Berry & Company Public Relations, LLC
Lynn Granito, 212-253-8881
lgranito(at)berrypr.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Icad Inc via GlobeNewswire
Datum: 05.05.2017 - 14:00 Uhr
Sprache: Deutsch
News-ID 540591
Anzahl Zeichen: 8966
contact information:
Town:
Nashua
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 252 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"First-Ever European Analysis of Electronic Brachytherapy Using the Xoft System for Endometrial and Cervical Cancer Treatment to be Presented at European Society for Radiotherapy & Oncology Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Icad Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
